Shares of Cerus Co. (NASDAQ:CERS) traded up 9.1% during trading on Wednesday . The stock traded as high as $3.89 and last traded at $4.20, 99,419 shares traded hands during trading. A decline of 96% from the average session volume of 2,301,612 shares. The stock had previously closed at $3.85.
Several brokerages have recently issued reports on CERS. Zacks Investment Research raised Cerus from a “sell” rating to a “hold” rating in a research note on Wednesday, March 18th. BTIG Research began coverage on Cerus in a research note on Wednesday, February 26th. They set a “buy” rating and a $7.00 price target on the stock. ValuEngine raised Cerus from a “hold” rating to a “buy” rating in a research note on Friday, January 3rd. Finally, BidaskClub lowered Cerus from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $7.33.
The company has a debt-to-equity ratio of 1.01, a current ratio of 2.55 and a quick ratio of 2.16. The firm has a market cap of $624.34 million, a price-to-earnings ratio of -8.38 and a beta of 1.19. The firm has a 50 day moving average price of $4.64 and a 200-day moving average price of $4.50.
Cerus (NASDAQ:CERS) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). Cerus had a negative net margin of 95.44% and a negative return on equity of 112.64%. The firm had revenue of $20.92 million for the quarter, compared to analyst estimates of $20.90 million. On average, sell-side analysts expect that Cerus Co. will post -0.44 EPS for the current fiscal year.
In other Cerus news, SVP Carol Moore sold 26,684 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $3.59, for a total value of $95,795.56. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Chrystal Menard sold 26,535 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $3.59, for a total value of $95,260.65. Following the completion of the transaction, the insider now directly owns 7,500 shares in the company, valued at approximately $26,925. The disclosure for this sale can be found here. Insiders have sold 187,855 shares of company stock worth $674,399 in the last ninety days. 7.26% of the stock is currently owned by insiders.
A number of large investors have recently added to or reduced their stakes in CERS. CVA Family Office LLC acquired a new position in Cerus in the fourth quarter valued at about $42,000. Great West Life Assurance Co. Can acquired a new stake in shares of Cerus during the fourth quarter worth about $44,000. Exchange Traded Concepts LLC acquired a new stake in shares of Cerus during the fourth quarter worth about $57,000. Virtu Financial LLC acquired a new stake in shares of Cerus during the fourth quarter worth about $77,000. Finally, Alpine Global Management LLC acquired a new stake in shares of Cerus during the fourth quarter worth about $78,000. 69.56% of the stock is currently owned by hedge funds and other institutional investors.
About Cerus (NASDAQ:CERS)
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Featured Article: How does the Federal Reserve determine interest rates?
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.